Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus.

Bonakdaran S, Hami M, Hatefi A.

Saudi J Kidney Dis Transpl. 2012 Nov;23(6):1215-20. doi: 10.4103/1319-2442.103562.

2.

25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.

Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17.

3.

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R.

Arch Intern Med. 1998 May 11;158(9):998-1004.

PMID:
9588433
4.

Impact of oral 1,25-dihydroxy vitamin D (calcitriol) replacement therapy on coronary artery risk factors in type 2 diabetic patients.

Bonakdaran S, Nejad AF, Abdol-Reza V, Hatefi A, Shakeri M.

Endocr Metab Immune Disord Drug Targets. 2013 Dec;13(4):295-300.

PMID:
24180458
5.

Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions.

Isakova T, Gutiérrez OM, Patel NM, Andress DL, Wolf M, Levin A.

J Ren Nutr. 2011 Jul;21(4):295-302. doi: 10.1053/j.jrn.2010.07.002. Epub 2010 Sep 3.

PMID:
20817560
7.

Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.

Salako BL, Finomo FO, Kadiri S, Arije A, Olatosin AO.

Afr J Med Med Sci. 2002 Mar;31(1):53-7.

PMID:
12518931
8.

Association between plasma oxidized low-density lipoprotein and diabetic nephropathy.

Ujihara N, Sakka Y, Takeda M, Hirayama M, Ishii A, Tomonaga O, Babazono T, Takahashi C, Yamashita K, Iwamoto Y.

Diabetes Res Clin Pract. 2002 Nov;58(2):109-14.

PMID:
12213352
9.
10.

Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.

Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D.

J Diabetes Complications. 2010 Sep-Oct;24(5):325-33. doi: 10.1016/j.jdiacomp.2009.04.001. Epub 2009 Jun 23.

PMID:
19553142
11.

Relationship between lipoprotein profile and urinary albumin excretion in type II diabetic patients with stable metabolic control.

Reverter JL, Sentí M, Rubiés-Prat J, Lucas A, Salinas I, Pizarro E, Pedro-Botet J, Romero R, Sanmartí A.

Diabetes Care. 1994 Mar;17(3):189-94.

PMID:
8174446
12.

The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.

Amador-Licona N, Guízar-Mendoza J, Vargas E, Sánchez-Camargo G, Zamora-Mata L.

Arch Med Res. 2000 Nov-Dec;31(6):571-5.

PMID:
11257323
13.

Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes?

Shehab D, Al-Jarallah K, Mojiminiyi OA, Al Mohamedy H, Abdella NA.

Diabet Med. 2012 Jan;29(1):43-9. doi: 10.1111/j.1464-5491.2011.03510.x.

PMID:
22050401
14.

Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus.

Resl M, Clodi M, Neuhold S, Kromoser H, Riedl M, Vila G, Prager R, Pacher R, Strunk G, Luger A, Hülsmann M.

Diabet Med. 2012 Jun;29(6):721-5. doi: 10.1111/j.1464-5491.2011.03515.x.

PMID:
22050532
16.

Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.

Tiryaki Ö, Usalan C, Sayiner ZA.

Ren Fail. 2016;38(2):222-7. doi: 10.3109/0886022X.2015.1128250. Epub 2015 Dec 27.

PMID:
26707134
17.

Is vitamin D status a predictor glycaemic regulation and cardiac complication in type 2 diabetes mellitus patients?

Yilmaz H, Kaya M, Sahin M, Delibasi T.

Diabetes Metab Syndr. 2012 Jan-Mar;6(1):28-31. doi: 10.1016/j.dsx.2012.05.007. Epub 2012 Jun 6.

PMID:
23014251
18.
19.

The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy.

Lv C, Zhou YH, Wu C, Shao Y, Lu CL, Wang QY.

Diabetes Metab Res Rev. 2015 Oct;31(7):717-24. doi: 10.1002/dmrr.2659. Epub 2015 Jun 25.

PMID:
25952368
20.

Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.

Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.

J Atheroscler Thromb. 2011;18(11):1018-28. Epub 2011 Sep 15.

Supplemental Content

Support Center